← back to search

Aïcha Goubar

King's College London · GB
Area of research
Molecular Biology · Cancer Research
Research interest
Research interests include RNA modifications and cancer, Cancer Genomics and Diagnostics, Hip and Femur Fractures, and Lung Cancer Treatments and Mutations.
h-index
27
citations
4,555
works
135
NIH funding
primary concept
email

Recent publications

A Randomized Trial of Intravenous Iron Supplementation and Exercise on Exercise Capacity in Iron-Deficient Nonanemic Patients With CKD
Kidney International Reports 2023cited by 17position: middledoi
Frequency, duration, and type of physiotherapy in the week after hip fracture surgery – analysis of implications for discharge home, readmission, survival, and recovery of mobility
Physiotherapy 2023cited by 9position: middledoi
Discharge after hip fracture surgery by mobilisation timing: secondary analysis of the UK National Hip Fracture Database
Age and Ageing 2020cited by 50position: middledoi
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials
Breast Cancer Research and Treatment 2017cited by 27position: middledoi
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials
Breast Cancer Research and Treatment 2017cited by 1position: middledoi
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials
Annals of Oncology 2015cited by 311position: lastdoi
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
Annals of Oncology 2015cited by 45position: middledoi
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Nature Medicine 2014cited by 1,022position: middledoi
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
Annals of Oncology 2014cited by 465position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Maria Vittoria Dieci · Burning Rock Biotech (China)5 papers (2014–2017)Valentina Guarneri · Mario Negri Institute for Pharmacological Research5 papers (2014–2017)Pierfranco Conté · Candiolo Cancer Institute5 papers (2014–2017) · 4 papers (2014–2017)Salma Ayis · King's College London3 papers (2020–2023)Suzette Delaloge · Institut Gustave Roussy3 papers (2014–2015) · 3 papers (2014–2015)Fabrice André · Institut Gustave Roussy3 papers (2014–2015)Antonio Frassoldati · University of Ferrara2 papers (2017–2017)Luigi Cavanna · Amgen (United States)2 papers (2017–2017)Catherine Sackley · University of Nottingham2 papers (2020–2023)Gaia Griguolo · Consorci Institut D'Investigacions Biomediques August Pi I Sunyer2 papers (2017–2017)Orouba Almilaji · University of London2 papers (2020–2023)Katie Jane Sheehan · Queen Mary University of London2 papers (2020–2023)Federico Piacentini · Ospedale Santa Chiara2 papers (2017–2017)Giuseppe Viale · European School of Oncology2 papers (2014–2015)Andrea Michelotti · Associazione Italiana Di Oncologia Medica2 papers (2017–2017)Carmen Criscitiello · Humanitas University2 papers (2014–2015)Giuseppe Curigliano · Istituti di Ricovero e Cura a Carattere Scientifico2 papers (2014–2015)Finbarr C. Martin · King's College London2 papers (2020–2023)